ALSO NOTED: Cell Therapeutics to bypass interim analysis; Nabi reports NicVAX data; Chinese see value in scientific failure; an

> Cell Therapeutics has decided to bypass an interim analysis of  its non-Hodglin's lymphoma drug candidate Pixantrone. Instead, researchers say they will conduct a full analysis after the trial is completed later this year. Report

> Nabi reports positive results from nine-month results for NicVAX. Report

> Chinese officials are mulling a new law that will officially sanction the value of scientific failure. FierceBioResearcher

> Innocoll is selling its CollaRx Gentamicin surgical implant and European sales and marketing infrastructure to EUSA Pharma. Release

> Pfizer announced results from a new trial that showed statin-switching isn't such a good idea. Lipitor patients who switched to simvastatin saw their risk of cardio events and death rise by almost a third. FiercePharma

> AstraZeneca announced it has issued $6.9 billion in bonds on the U.S. market, planning to use the proceeds to retire a chunk of the short-term debt it took on for the $15 billion MedImmune buyout. Report

And Finally... It's tough enough worrying that the fellow in the next desk will beat you to that promotion--and now, Pfizerites have to worry about a colleague stealing their identities, too. Report